Synaptic Resilience Enhancement Protocol

Overview

This therapeutic concept proposes synaptic resilience enhancement for individuals identified as pre-symptomatic for neurodegenerative diseases. By targeting synaptic proteins (neurogranin), receptors, and downstream signaling pathways before significant synapse loss occurs, this approach aims to preserve cognitive function and prevent progression to clinical disease.^{1Synucleins in ocular tissues.2001 · J Neurosci Res · DOI 10.1002/jnr.1129 · PMID 11433431Open reference}

Rationale

• Synapse loss correlates with cognitive decline: Post-mortem studies show synapse loss is the strongest correlate of cognitive impairment in both AD and PD^{2Citation2014}

• Neurogranin is an early biomarker: Elevated CSF neurogranin predicts future cognitive decline in pre-symptomatic individuals^{3Citation2015}

• Synaptic plasticity is modifiable: NMDA receptor modulation, BDNF signaling, and synaptic protein synthesis can be enhanced pharmacologically^{4LTP and LTD: an embarrassment of riches.2004 · Neuron · DOI 10.1016/j.neuron.2004.09.012 · PMID 15450156Open reference}

• Early intervention critical: Synapse loss becomes irreversible once advanced; pre-symptomatic intervention offers the best chance of preservation^{5Citation2002}

Mechanistic Logic

flowchart TD
    subgraph Risk_Identification
        A["Cognitive Testing<br/>RAVLT, ECAS"] --> B["CSF Neurogranin<br/>Elevated = synaptic vulnerability"]
        B  -->  C["High Synaptic Risk"]
    end

    subgraph I["ntervention"]
        C  -->  D["NMDA Modulation<br/>Low-dose memantine"]
        C  -->  E["BDNF Enhancement<br/>Exercise, pharmacologic"]
        C  -->  F["Synaptic Protein Stabilization<br/>CK2 inhibition"]
    end

    subgraph M["echanisms"]
        D  -->  G["Enhance NMDA Signaling"]
        E  -->  H["Boost Synaptic Plasticity"]
        F  -->  I["Protect Synaptic Architecture"]
    end

    subgraph O["utcome"]
        G  -->  J["Preserved Synaptic Density"]
        H  -->  J
        I  -->  J
        J  -->  K["Maintained Cognitive Function"]
    end

Target Population

Key Components

Pharmacologic Interventions

1. Low-dose memantine: Sub-antagonistic NMDA doses that enhance synaptic plasticity without causing adverse effects^{6Migraine prevalence, disease burden, and the need for preventive therapy.2007 · Neurology · DOI 10.1212/01.wnl.0000252808.97649.21 · PMID 17261680Open reference}

2. Lobeline: Amphetamine derivative that enhances dopamine release and protects synapses^{7[Psychiatric emergencies: challenges and vicissitudes].2010 · Braz J Psychiatry · DOI 10.1590/s1516-44462010000600001 · PMID 21140072Open reference}

3. NSI-189: Novel compound that promotes hippocampal neurogenesis and synaptic protein expression^{8Citation2017}

4. Sage-217 (SAGE-217): GABA-A modulator in development for cognitive enhancement^{92018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis.2018 · Ann Rheum Dis · DOI 10.1136/annrheumdis-2018-213585 · PMID 29997112Open reference}

Amplification Approaches

• CK2 inhibition: Enhance synaptic protein synthesis and stability^{10Citation2012}

• mGluR5 positive allosteric modulators: Enhance glutamate-dependent plasticity^{2Citation2014}0

• ** PDE5 inhibitors**: Enhance cGMP signaling to support synaptic plasticity^{2Citation2014}1

Non-Pharmacologic Adjuncts

• Cognitive training: Structured cognitive exercises to maintain synaptic networks

• Aerobic exercise: Increases BDNF and promotes synaptic plasticity^{2Citation2014}2

• Sleep optimization: Sleep-dependent synaptic downscaling and memory consolidation

Monitoring Biomarkers

• CSF: Neurogranin, synaptic vesicle proteins (SV2C, synaptotagmin)

• Blood: BDNF, NFL for general neurodegeneration

• Imaging: Synaptic PET (SV2A ligands), FDG-PET for hypometabolism

• Cognitive: RAVLT, ECAS, MDS-UPDRS cognitive subscale

Clinical Trial Design

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways